Author

Oyinkan Solanke

Observed names: O Solanke, Oyinkansola Solanke

Institution: Ipsen (United Kingdom)

Observed institutions: Ipsen (France), Ipsen (United Kingdom), Imperial Consultants

ORCID: 0009-0004-2655-9512

Observed ORCID: 0009-0004-2655-9512

OpenAlex ID: A5050988851

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK

2020 · Elisabeth Fenwick, Alan Martin, et al. · ERJ Open Research · 22

The socioeconomic impacts of fibrodysplasia ossificans progressiva: evidence from a retrospective case-control study in France

2026 · Geneviève Baujat, Stéphane Bouée, et al. · JBMR Plus · 1

Development of the Fibrodysplasia Ossificans Progressiva FLare EXperience Revised (FOP-FLEX-R©) Questionnaire: A Patient-Reported Outcome Measure

2026 · Robert J. Pignolo, Edward C. Hsiao, et al. · Bone

Ee187 Predicted Lifetime Health Care Resource Use Costs Associated With the Treatment of Patients With Primary Biliary Cholangitis From a Uk Payer Perspective

2025 · Oyinkan Solanke, James Gould, et al. · Value in Health

Alkaline phosphatase and bilirubin as predictors of long-term outcomes in primary biliary cholangitis: A systematic literature review

2025 · Jörn Schattenberg, Oyinkan Solanke, et al. · Zeitschrift für Gastroenterologie

A Review of Aneurysmal Subarachnoid Hemorrhage Managed in Resource Challenged Setting

2021 · Ugwuanyi Cu, Anigbo Aa, et al. · Clinics in Surgery

Cost-Effectiveness of a Single Inhaler Triple Therapy vs a Dual Inhaled Corticosteroid Plus Long-Acting Beta Agonist (ICS/LABA) for Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom (UK)

2018 · E Fenwick, AA Martin, et al. · Value in Health

Works count: 7

Citation count: 23

H-index: 1

I10-index: 1